Controlled release indomethacin

ABSTRACT

In accordance with the present invention, the controlled release formulation contains coated pellets of indomethacin of only one type. The pellet releases indomethacin in both immediate and sustained release form. The immediate release indomethacin is rapidly absorbed from the stomach to provide a bolus dose of active agent. The sustained release indomethacin is gradually released over time to maintain the blood levels at effective concentrations for long periods of time.

BACKGROUND OF THE INVENTION

This invention relates to a novel oral pharmaceutical formulation ofindomethacin having controlled release properties.

The formulation is directed to a coated pellet from which apharmaceutical compound is slowly released over time. This formulationhas been shown to exhibit excellent controlled release properties. Theformulation provides an immediate release indomethacin for elevatingblood levels to pharmacologically effective levels and sustained releaseindomethacin for maintaining those levels.

It has long been known that almost all pharmacologically activecompounds are most effective when present in plasma within a certainconcentration range. Above this range, there sometimes may be a dangerthat deleterious side effects may become manifest and even when there isnot the danger, excess drug in the blood plasma may be wasted if theconcentration is significantly above the blood level that results in themaximum pharmacological effect. Below this range, there often may be adanger that the active agent may not be maximally effective or eveneffective at all.

An oral dosage form is the preferred route of administration ofpharmaceutical compounds because it provides easy, low costadministration. However, patient compliance becomes an important factorto consider in conjunction with oral administration of a pharmaceuticalcompound, especially if the compound must be taken three or four times aday. To maximize patient compliance, here, one attempts to reduce thenumber of dosage forms a patient must take to attain effective therapy,while at the same time provide an oral dosage form which is palatable tothe patient.

One method of accomplishing this goal is the use of sustained releaseformulations which have been numerously described in the prior art. Manyof these formulations are comprised of a solid, polymeric matrixthroughout which a pharmaceutical compound has been dispersed. After theformulation is ingested, the active pharmaceutical compound will slowlyrelease from the polymer matrix, resulting in prolonged release of theactive agent.

The indomethacin controlled release formulations of the presentinvention comprise a capsule having coated pellets which exhibit bothimmediate release and sustained release characteristics in the samecapsule. The immediate release of indomethacin provides elevated bloodlevels within about 2 hours after ingestion. The sustained releasemaintains the blood levels of indomethacin for longer periods of timethan the prior art compounds.

Indomethacin has been the most successful non-steroidalanti-inflammatory agent available for the treatment of rheumatoidarthritis, osteoarthritis, as well as other anti-inflammatory diseases.The administration of indomethacin in traditional capsule or tabletform, to maintain effective blood levels of active agent, requires theingestion of a capsule three or four times a day. Most patients beingtreated on this drug regimen are elderly and often must take severalother capsules or tablets for the treatment of other conditions ordisease states. Accordingly, it is important for the convenience of thepatient and to ensure compliance that the frequency of administration bekept to a minimum.

It is also important to maintain a continuous anti-inflammatory serumconcentration of indomethacin. This is particularly difficult toaccomplish with the traditional pharmaceutical forms of indomethacinwhich are rapidly absorbed. These traditional forms result in initialhigh plasma concentrations of indomethacin which are then slowlymetabolized to low blood levels. The length of time that indomethacinblood levels are at effective concentrations is far from optimal.

It is therefore an object of this invention to provide a pharmaceuticalcomposition of indomethacin with both sustained release properties andrapid release properties in one capsule which is orally active. It is afurther object of this invention to provide plasma concentrations ofindomethacin which are pharmacologically effective for the longestduration of time.

It is a further object of this invention to provide a controlled releasecapsule of indomethacin that can be administered only once a day.

It is also an object of this invention to provide a method for producingthe novel sustained release formulation of this invention.

SUMMARY OF THE INVENTION

In accordance with the present invention, the controlled releaseformulation contains coated pellets of indomethacin of only one type.The pellet releases indomethacin in both immediate and sustained releaseform. The immediate release indomethacin is rapidly absorbed from thestomach to provide a bolus dose of active agent. The sustained releaseindomethacin is gradually released over time to maintain the bloodlevels at effective concentrations for long periods of time.

The pellet is comprised of a non-pareil or sugarbased which supportsindomethacin and a binder agent. This indomethacin loaded pellet is thensubsequently coated with a mixture of hydroxypropyl cellulose, ethylcellulose, and a plasticizer, for example, propylene glycol.

The bolus dose is rapidly released allowing the blood levels to quicklyelevate to effective concentrations. The ratio of the cellulosecompounds determines the rate of release of compound. In general, up to40% by weight of the total indomethacin is released immediately andpreferably between about 20% and 40% of the indomethacin is releasedimmediately, whereas about 60% to about 80% of indomethacin releases ina controlled fashion. The formulation of the present invention may beused with any active pharmaceutical composition having physicochemicalproperties similar to indomethacin.

The present invention exhibits four advantages over the compounds of theprior art. First, the invention provides for a controlled release pelletwith both immediate and sustained release characteristics. This avoidsthe need to manufacture two pellets as provided by the prior artmethods. Second, the invention provides a simple and efficient methodfor changing the release characteristics of the pellet. With minormodification, the pellet can exhibit zero order or first order release.Third, it is possible to vary the rate of release, i.e., and change therelease characteristics by simply modifying the amounts of the cellulosepolymers used to formulate the pellet. Fourth, the controlled releasecapsules of the present invention can maintain effective blood levels ofindomethacin with the administration of only one capsule or tablet perday.

DETAILED DESCRIPTION OF THE INVENTION

The present invention comprises a controlled release capsule ofindomethacin having a pellet which rapidly releases indomethacin andreleases indomethacin in a controlled release fashion. The pellet isproduced in two stages. In the first stage, indomethacin is sprayed ontoa non-pareil or sugar-based pellet in combination with a binder agent.In the second stage, the loaded pellets produced in the first stage arecoated with a mixture of hydroxypropyl cellulose and ethyl cellulose.The resulting pellet surprisingly exhibits both immediate releasecharacteristics and sustained release characteristics. About 20 to 40percent of the indomethacin in the pellets is released in immediaterelease fashion. The formulation of the present invention may be usedwith any active agent having physicochemical properties similar toindomethacin.

The controlled release capsule formulation is comprised of a total unitdose of indomethacin, i.e., about 25 to 150 mg. The controlled releasepellet of the present invention is comprised of a commercial non-pareilor sugarbased pellet coated by a mixture comprised of indomethacin and abinding agent which binds the indomethacin to the non-pareil pellet. Thepreferred binding agent is hydroxypropyl methyl cellulose, although anumber of other hydrophilic polymers may be used including hydroxymethylcellulose, hydroxyethyl cellulose, and polyvinyl pyrrolidone, amongothers. In general, the binding agent comprises between about 1% and 10%by weight of the first stage pellet. Preferably, the binding agentcomprises about 3.5% to 4.0% by weight of the first step pellet.

Preferred non-pareil pellets are commercially available from a number ofpharmaceutical supply houses. Non-pareil pellets of particle size 20-25mesh are particularly preferred, though any non-pareil pellet of meshsize within the range of 14 mesh to 60 mesh are useful in embodiments ofthis invention.

The first step indomethacin loaded pellets of the present invention areprepared by coating non-pareil pellets (preferrably within theabove-mentioned particle size range of 14 mesh to 60 mesh size) in afluid bed equipment (Glatt GPC6 5/9, Glatt Air Techniques, Ramsey,N.J.). A suspension composed of hydroxypropylmethyl cellulose, 6 cps,Pharmacoat™ 606 available from Shinetsu, Tokyo, Japan is dissolved in a50/50 mixture of water and ethanol. Micronized indomethacin is thensuspended in the above prepared solution. A number of other solvents maybe used to prepare the first step indomethacin loaded pellet, includinga mmixture of water and acetone, among other aqueous based solvents. Thesuspension is sprayed onto the non-pareil pellets to produce theindomethacin loaded pellets. Preferably, the loaded pellets are composedof about 2% to about 10% by weight (total weight of the pellet) binder,preferably hydroxypropyl cellulose, 6 cps, and 5 to 30% by weightindomethacin. Most preferably, indomethacin comprises about 25% byweight.

After the pellets are loaded in the first stage, the pellets are thencoated with a mixture of ethyl cellulose, 10 cps, hydroxypropylcellulose (Klucel EF, available from Hercules Corp., Wilmington, Del.),and propylene glycol. The ratio of ethyl cellulose to Klucel EF in thissecond stage coating of the pellet ranges from 50:50 to 90:10. In themost preferred embodiments, the amounts of ethyl cellulose range fromabout 65% to about 75% of the total weight of ethyl cellulose andhydroxypropyl cellulose combined, but the actual ratio used depends onthe controlled release characteristics desired. The final ratio of ethylcellulose to hydroxypropyl cellulose in solution reflects the finalratio of these cellulose polymers in the final pellet. The second stagecoating of ethyl cellulose and Klucel EF may range from 0.5% to 10% byweight of the first stage coated pellet and preferably ranges from 2% to5% by weight of the first stage coated pellet.

The second stage indomethacin pellets are prepared by coating the firststep rapid release pellets prepared above. The coating is prepared bydissolving ethyl cellulose, 10 cps, propylene glycol, and hydroxypropylcellulose (Klucel™ EF) in 95% ethanol, or another polar, protic solvent.The preferred second stage coating solution is comprised of 3.75% (basedon the weight of alcohol as solvent)ethyl cellulose 10 cps, 1.25% KlucelEF and 0.5% propylene glycol dissolved in 95% ethanol. This solution issprayed onto the rapid release indomethacin loaded pellets in a fluidbed equipment using a Wurster column. The second stage solution maycomprise between about 0.5% and 25% ethyl cellulose and about 0.5% and25% hydroxypropyl cellulose by weight of the solution. The final ratioof ethyl cellulose to hydroxypropyl cellulose in solution reflects thefinal ratio of these cellulose polymers in the final pellet.

The pellets are dried after spraying. They are then weighed outaccording to the dose of indomethacin to be administered, diluent may beadded, for example dextrose, sorbitol, mannitol, among other commondiluents, and the mixture is pressed into tablets. Alternatively, themixture can be encapsulated in a hard gelatin capsule.

The effect of varying the ratio of ethyl cellulose to Klucel EF onrelease rates is demonstrated in FIG. 1. FIG. 1 demonstrates the releaserate when 60% and 100% of the second stage controlled release solution,corresponding to 3% and 5%, respectively, of final weight polymerexpressed as a percentage of the weight of the first stage indomethacinloaded pellet is coated onto the pellet. These profiles illustrate theflexibility of release rates offered by the present invention.

FIG. 2 demonstrates the superior controlled release qualities exhibitedby indomethacin pellets of the present invention versus prior artsustained release capsules. Examples A and B of FIG. 2 represent releaserates of pellets coated with 40% of the solution in example 3corresponding to a 2% final weight of polymer by weight of the firststage loaded pellet. It is noted that the formulations of the presentinvention not only provide immediate release of indomethacin, but alsoprovide a highly desired zero order rate of release compared to theprior art (Merck Sharp & Dohme sustained release capsule).

Illustrating the invention are the following examples. These examplesare for aiding the understanding of the invention, and are not to beconstrued as limiting the invention to their details.

PREPARATION OF INDOMETHACIN LOADED PELLETS EXAMPLE 1

    ______________________________________                                        Indomethacin (micronized)                                                                              750    g                                             Polyvinylpyrrollidone (Povidone)                                                                       150    g                                             Water                    1500   ml                                            Alcohol                  1500   ml                                            Non-pareils (20-25 mesh) 3000   g                                             ______________________________________                                    

Povidone is dissolved in water-alcohol mixture followed by dispersingindomethacin. This suspension is sprayed onto non-pareil pellets in afluid bed equipment (Glatt GPCG 5/9) using a Wurster insert. The pelletsare dried at a temperature below 60° C.

EXAMPLE 2

    ______________________________________                                        Indomethacin (micronized)                                                                              750    g                                             Hydroxypropylmethylcellulose, 6 cps                                                                    150    g                                             Water                    1500   ml                                            Alcohol                  1500   ml                                            Non-pareils (20-25 mesh) 3000   g                                             ______________________________________                                    

Preparation: Procedure is the same as that described in Example 1 excepthydroxypropylmethylcellulose is substituted for Povidone.

PREPARATION OF CONTROLLED RELEASE INDOMETHACIN PELLETS EXAMPLE 3

    ______________________________________                                        Ethyl cellulose, 10 cps                                                                              112.50  g                                              Hydroxypropyl cellulose                                                                              37.50   g                                              (Klucel ™ EF)                                                              Propylene Glycol       15.00   g                                              Indomethacin Loaded    3000.00 g                                              Pellets                                                                       Ethyl Alcohol          3000.00 ml                                             ______________________________________                                    

Dissolve Klucel™ EF and ethyl cellulose in alcohol, add propylene glycoland spray resultant solution onto indomethacin loaded pellets in a fluidbed equipment (Glatt GPCG 5/9) using a Wurster insert.

EXAMPLE 4

    ______________________________________                                        Ethyl cellulose, 10 cps                                                                              97.50   g                                              Hydroxypropyl cellulose                                                                              52.50   g                                              (Klucel ™ EF)                                                              Propylene Glycol       15.00   g                                              Indomethacin Loaded    3000.00 g                                              Pellets                                                                       Ethyl Alcohol          3000.00 ml                                             ______________________________________                                    

Procedure is the same as that described in Example 3

EXAMPLE 5

    ______________________________________                                        Ethyl cellulose, 10 cps                                                                              75.00   g                                              Hydroxypropyl cellulose                                                                              75.00   g                                              (Klucel EF)                                                                   Propylene Glycol       15.00   g                                              Indomethacin Loaded    3000.00 g                                              Pellets                                                                       Ethyl Alcohol          3000.00 g                                              ______________________________________                                    

Procedure is the same as that described in Example 3.

The ratio of ethyl cellulose to Klucel™ EF exemplified in Examples 3, 4and 5 is 75:25, 65:35 and 50:50 respectively.

What is claimed is:
 1. An indomethacin controlled release formulation consisting essentially of:(a) one type of indomethacin containing pellet one which exhibits both immediate release and sustained release characteristics comprising(1) a non-pareil pellet; (2) a first coating comprised of about 5% to about 30% by weight of said pellet and first coating of indomethacin and about 2% to 10% by weight of a binding agent; and (3) A second coating comprised of a mixture of ethyl cellulose and hydroxypropyl cellulose in a weight ratio range of about 50:50 to about 90:10.
 2. The formulation according to claim 1 wherein said binding agent comprises about 3% to 4% by weight of said pellet and first coating.
 3. The formulation according to claim 1 wherein said mixture of ethyl cellulose and hydroxypropyl cellulose comprises about 2% to about 5% of the weight of said pellet and first coating.
 4. The formulation according to claim 2 wherein said binding agent is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and polyvinylpyrrolidone. 